First patient dosed in bemcentinib COVID-19 trial
Bemcentinib was selected as the first candidate to be tested as part of the UK ACcelerating COVID-19 Research & Development platform (ACCORD) study
Read More
Tag: BerGenBio
Bemcentinib first candidate to be tested in unique ACCORD study
ACCORD is a multicentre, seamless, Phase II adaptive randomisation platform trial to assess the efficacy and safety of multiple candidate agents
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
